Aim To investigate the impact of PD-L1 expression status on consolidative durvalumab
efficacy and safety in stage III NSCLC patients. Methods This retrospective, ethics board …

To the Editor: Antonia et al.(Nov. 16 issue) 1 found that, among patients with locally
advanced, unresectable, stage III non–small-cell lung cancer (NSCLC), the median …

Background In the ongoing, phase 3 PACIFIC trial, durvalumab improved the primary
endpoints of progression-free survival and overall survival compared with that for placebo …

The pivotal PACIFIC trial defined durvalumab consolidation as the new standard of care in
patients with stage III non-small-cell lung cancer treated with definitive radiochemotherapy …

Introduction For patients with unresectable, stage III non-small-cell lung cancer (NSCLC),
current standard of care is concurrent chemoradiotherapy (cCRT) followed by consolidation …

Background Durvalumab following concurrent chemoradiotherapy is standard treatment for
unresectable stage III non‐small‐cell lung cancer based on the results of the PACIFIC trial …

Background In the PACIFIC trial, durvalumab significantly improved progression-free and
overall survival (PFS/OS) versus placebo, with manageable safety, in unresectable, stage III …

Background Compared to a placebo, durvalumab has been reported to significantly prolong
progression-free and overall survival in patients with stage III unresectable non-small cell …

Background: For eligible patients with unresectable stage III non-small-cell lung cancer,
durvalumab consolidation therapy following chemoradiotherapy is the standard of care …

Background Immune checkpoint inhibitors are a new standard of care for patients with
advanced non-small-cell lung cancer (NSCLC) without EGFR tyrosine kinase or anaplastic …